In This Section

Myeloma and Plasma Cell Dyscrasias

In association with Blood Cancer Discovery

November 3-5, 2022 
Westin Copley Place 
Boston, Massachusetts

Advance Registration DeadlineFriday, September 30, 2022


Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts

Myeloma is one of the most commonly diagnosed blood cancers in the United States, with an estimated 34,470 new cases in 2022. Patient outcomes have improved over the last few years due to the development and FDA approval of novel therapeutics such as immunomodulatory agents (lenalidomide), immunotherapeutics (daratumumab), and proteasome inhibitors (bortezomib). New therapeutic options remain a priority to counter a lack of response to treatment and treatment resistance or relapse.  

This meeting will expand upon the virtual meeting on this topic held in April 2021 (due to COVID) and will be the first AACR in-person meeting focused on myeloma. Topics presented at the virtual meeting with be updated and expanded during the in-person meeting and will focus on the areas of disease progression, drug resistance, epigenetics, genomics, immunotherapy, microenvironment, and novel therapeutics. A special session on the future of myeloma clinical trials will include representatives from regulatory agencies, academia, and industry to discuss minimal residual disease, trial endpoints, early / late intervention, and clinical issues related to disease maintenance. 

Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be captured and made available as an on-demand program after the meeting. Visit registration for details. 

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available